ALLEN, Texas, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that for the second quarter ended June 30, 2021, revenues totaled $42.7 million compared with $38.0 million for the same period in 2020. Net income for the second quarter of 2021 totaled $8.9 million as compared to $8.6 million for the same period in 2020, with diluted earnings per share for the second quarter of 2021 at $4.88 compared to $4.68 for the second quarter of 2020.
Commenting on results for the second quarter of 2021, David Battat, President and CEO, stated, "In our press release announcing first quarter 2021 results, we highlighted that after three consecutive pandemic quarterly declines in sales during 2020, we turned the corner in early 2021 and expected continued improvements as the year progressed. I am especially pleased that we met those expectations in the second quarter of this year with sequential increases of 9% in revenues, 10% in operating income and 16% in net income." Mr. Battat continued, "When comparing our quarterly results to the second quarter of 2020, revenues were up 12% while other measurements were mixed, reflecting increased manufacturing and other personnel costs to support the safety and financial needs of our employees due to the continuing pandemic."
Addressing the outlook for the remainder of 2021, Mr. Battat added, "Barring major disruptions due to COVID-19, we expect the remaining quarters of the year to show increases in sales and operating income of approximately 25% compared to the same quarters in 2020. Consistent with our prior practices, we will return capital to our stockholders through increasing dividends and opportunistic purchases of our stock. Cash and short and long term investments totaled $80.0 million as of June 30, 2021, following the purchases of 17,123 shares of our common stock in the second quarter at an average price of $613 per share, for a total cost of $10.5 million."
Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com.
Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion's expectations regarding results for the remaining quarters of 2021 and return of capital through increasing dividends and stock repurchases. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.
Vice President and Chief Financial Officer
ATRION CORPORATION UNAUDITED CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data)
Three Months Ended June 30,
Six Months Ended June 30,
Cost of goods sold
Interest and dividend income
Other investment income (loss)
Income before income taxes
Income tax provision
Income per basic share
Weighted average basic shares outstanding
Income per diluted share
Weighted average diluted shares outstanding
ATRION CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands)